chevron_leftBack
As of 14 June 2026, Equillium, Inc. has a market cap of $131.51M USD, ranking #23697 globally and #3729 in the United States.
It ranks #2127 in the Healthcare sector, and #411 in the Biotechnology industry.
Key Stats
Market Cap
$131.51MUSD
Enterprise Value
$100.69MUSD
EBITDA (TTM)
-$23.52MUSD
Net Income (TTM)
-$22.4MUSD
PB Ratio
4.4
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Bruce Steel
open_in_new
Employees
35
Founded
2017
IPO
11 Oct 2018
Website
equilliumbio.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 1.5% | -11% | 11% | 49% | 54% | 354% |
News
Loading...
EQ Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
EQ
Equillium Inc
ISIN: US29446K1060
Shares Out.:
Shares Outstanding:
63.227M1
Shares Float:
48.484M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
2.08 USD | |
|
0A4D
Equillium Inc
ISIN: US29446K1060
|
2.06 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Equillium, Inc.
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
139K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
122K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
21K%
|
-
|
|
NYSE: IQV
|
$26.3B
20K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
19K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
14K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
36K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
34K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
32K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
32K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
21K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
19K%
|
-
|
chevron_leftBack